Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03239379 | A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects | PHASE1 | COMPLETED | 32 | — | — | Oct 30, 2017 | Mar 8, 2018 | May 15, 2018 | 1 | United States |
general safety evaluation by principal investigator
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Normal saline |
| BNZ132-1-40 | EXPERIMENTAL | PEGylated BNZ-1 for Injection |
| Name | Type | Description |
|---|---|---|
| BNZ132-1-40 | DRUG | Injectable peptide antagonist of IL-2, IL-9 and IL-15 |
| Placebo | DRUG | Normal Saline |
Inclusion Criteria: 1. Non-smoker. 2. Weight ≤100 kg (due to drug supply limitations). 3. Body Mass Index (BMI) ≥19 and \<35 kg/m2. 4. Healthy as determined by medical evaluation including medical history, physical examination, clinical laboratory tests, vital signs (pulse rate, blood pressure, res...